--- title: "Adjuvant Metastatic Urothelial Cancer CA244-0012 IZABRIGHT-Bladder01 | Sutter Health" description: "IZABRIGHT-Bladder01: A Randomized, Open-label, Phase 2/3 Trial of Izalontamab Brengitecan Versus Platinum-based Chemotherapy for Metastatic Urothelial Cancer in Participants With Disease Progression on or After an Immunotherapy-based Treatment" url: "https://www.sutterhealth.org/research/clinical-trials/adjuvant-metastatic-urothelial-cancer-ca244-0012-izabright-bladder01-2060655471" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Clinical trials](https://www.sutterhealth.org/research/clinical-trials) / 4. Adjuvant Metastatic Urothelial Cancer CA244-0012 IZABRIGHT-Bladder01 # Adjuvant Metastatic Urothelial Cancer CA244-0012 IZABRIGHT-Bladder01 **Status:** Closed to Enrollment #### Study details View study details on [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07106762). #### Locations - Sacramento - Palo Alto - Santa Rosa #### Clinical trial FAQs Information for patients and study volunteers, including [frequently asked questions](https://www.sutterhealth.org/research/faqs). ****TEMPORARILY CLOSED TO ENROLLMENT**** IZABRIGHT-Bladder01: A Randomized, Open-label, Phase 2/3 Trial of Izalontamab Brengitecan Versus Platinum-based Chemotherapy for Metastatic Urothelial Cancer in Participants With Disease Progression on or After an Immunotherapy-based Treatment ![Nitin Rohatgi, M.D., MBA](https://dyn.mktgcdn.com/p/tVS4RemP6bkC55e_mitBU2bV-F97uZqUB_hdGp4TZ6s/fit=crop,gravity=auto,dpr=2,width=188,height=250,quality=100) Nitin Rohatgi, M.D., MBA Principal investigator [View profile](https://www.sutterhealth.org/research/investigators/nitin-rohatgi-md-mba-1049681017) ## Sub-Investigators [Ari D Baron, M.D.](https://www.sutterhealth.org/research/investigators/ari-d-baron-md-1049681174) , [Zeyad H Kanaan, M.D.](https://www.sutterhealth.org/research/investigators/zeyad-h-kanaan-md-1049681222) , [Roozbeh Mohajer, M.D.](https://www.sutterhealth.org/research/investigators/roozbeh-mohajer-md-2015847331) ## Related clinical trials [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) - Clinical trial ### [Muscle-Invasive Bladder Cancer EV-309](https://www.sutterhealth.org/research/clinical-trials/muscle-invasive-bladder-cancer-ev-309-2087171931) A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE ENFORTUMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PARTICIPANTS WITH MUSCLE-INVASIVE BLADDER CANCER WHO ARE INELIGIBLE FOR OR HAVE ELECTED NOT TO UNDERGO CYSTECTOMY **Status:** Open to Enrollment - Clinical trial ### [Advanced Cervical Cancer NRG GY037](https://www.sutterhealth.org/research/clinical-trials/advanced-cervical-cancer-nrg-gy037-2097344123) A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer **Status:** Open to Enrollment - Clinical trial ### [Advanced Staged Cancer Targeted Therapy ASCO TAPUR](https://www.sutterhealth.org/research/clinical-trials/targeted-agent-and-profiling-utilization-registry-tapur-st-1049141787) Targeted Agent and Profiling Utilization Registry (TAPUR) Study **Status:** Open to Enrollment - Clinical trial ### [Adverse Effects of Chemotherapy Shengbai Solution](https://www.sutterhealth.org/research/clinical-trials/adverse-effects-of-chemotherapy-shengbai-solution-1097505286) A Randomized, Blinded, Placebo-controlled Trial of Shengbai Oral Formula to Assess Safety and Alleviation of Adverse Effects in Patients With Cancer Undergoing Chemotherapy **Status:** Open to Enrollment - Clinical trial ### [Acute Myeloid Leukemia Dental Wipes COG ACCL2531](https://www.sutterhealth.org/research/clinical-trials/acute-myeloid-leukemia-dental-wipes-cog-accl2531-2099128841) A Randomized Double-Blinded Trial of Xylitol Dental Wipes for the Prophylaxis of Bloodstream Infections From Oral Organisms in Pediatric Patients With Acute Myeloid Leukemia **Status:** Open to Enrollment [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-metastatic-urothelial-cancer-ca244-0012-izabright-bladder01-2060655471#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Clinical trials","item":"https://www.sutterhealth.org/research/clinical-trials"},{"@type":"ListItem","position":4,"name":"Adjuvant Metastatic Urothelial Cancer CA244-0012 IZABRIGHT-Bladder01"}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalWebPage","@id":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-metastatic-urothelial-cancer-ca244-0012-izabright-bladder01-2060655471#medicalwebpage","name":"Adjuvant Metastatic Urothelial Cancer CA244-0012 IZABRIGHT-Bladder01","description":"IZABRIGHT-Bladder01: A Randomized, Open-label, Phase 2/3 Trial of Izalontamab Brengitecan Versus Platinum-based Chemotherapy for Metastatic Urothelial Cancer in Participants With Disease Progression on or After an Immunotherapy-based Treatment","url":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-metastatic-urothelial-cancer-ca244-0012-izabright-bladder01-2060655471","inLanguage":"en-US","dateModified":"2026-08-24","publisher":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"},"medicalAudience":{"@type":"MedicalAudience","audienceType":"Patient"},"mainEntity":{"@id":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-metastatic-urothelial-cancer-ca244-0012-izabright-bladder01-2060655471#medicaltrial"},"breadcrumb":{"@id":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-metastatic-urothelial-cancer-ca244-0012-izabright-bladder01-2060655471#breadcrumblist"},"mentions":[{"@type":"Person","name":"Nitin Rohatgi, M.D., MBA","url":"https://www.sutterhealth.org/research/investigators/nitin-rohatgi-md-mba-1049681017","jobTitle":"Principal Investigator","affiliation":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"}}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalTrial","@id":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-metastatic-urothelial-cancer-ca244-0012-izabright-bladder01-2060655471#medicaltrial","name":"Adjuvant Metastatic Urothelial Cancer CA244-0012 IZABRIGHT-Bladder01","alternateName":"IZABRIGHT-Bladder01: A Randomized, Open-label, Phase 2/3 Trial of Izalontamab Brengitecan Versus Platinum-based Chemotherapy for Metastatic Urothelial Cancer in Participants With Disease Progression on or After an Immunotherapy-based Treatment","url":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-metastatic-urothelial-cancer-ca244-0012-izabright-bladder01-2060655471","description":"TEMPORARILY CLOSED TO ENROLLMENT IZABRIGHT-Bladder01: A Randomized, Open-label, Phase 2/3 Trial of Izalontamab Brengitecan Versus Platinum-based Chemotherapy for Metastatic Urothelial Cancer in Participants With Disease Progression on or After an Immunotherapy-based Treatment","identifier":"NCT07106762","code":{"@type":"MedicalCode","codeValue":"NCT07106762","codingSystem":"ClinicalTrials.gov"},"sameAs":"https://clinicaltrials.gov/study/NCT07106762","status":"https://schema.org/ActiveNotRecruiting","healthCondition":[{"@type":"MedicalCondition","name":"Urologic Diseases"},{"@type":"MedicalCondition","name":"Urothelial Cancer"}],"studyLocation":[{"@type":"AdministrativeArea","name":"Sacramento"},{"@type":"AdministrativeArea","name":"Palo Alto"},{"@type":"AdministrativeArea","name":"Santa Rosa"}]} ```